Trial Profile

A phase Ib, multiple-ascending dose (MAD), double-blind, randomized, placebo-controlled study of PXL065 in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pioglitazone deuterated (Primary) ; Pioglitazone
Indications Adrenomyeloneuropathy; Non-alcoholic steatohepatitis
Focus Adverse reactions; Pharmacokinetics
Sponsors Poxel

Most Recent Events

16 Nov 2020 According to a Poxel media release, full set of data from this study is in line with our topline analysis.
16 Nov 2020 Results presented in a Poxel media release.
16 Nov 2020 According to a Poxel media release, data from this study were presented at The Liver Meeting Digital Experience 2020 in association with the American Association for the Study of Liver Diseases (AASLD).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com